Skip to main content
TipRanks
Go Ultimate75% OFF

Syndax Pharmaceuticals (SNDX) Drug Pipeline

1,061 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Revumenib, Sndx-5613Acute Leukemia, Refractory Leukemia, Relapsed/Refractory (R/R) Hematologic Malignancies, Relapsed LeukemiaPhase INot Yet RecruitingA Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal ImpairmentOct 28, 2026―
Revumenib, Intensive Chemotherapy RegimenAcute Myeloid LeukemiasPhase IIIRecruitingStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationSep 30, 2025
Sndx-5613, Chemotherapy Regimen, HidacAcute Myeloid LeukemiasPhase IActive Not RecruitingA Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasJan 12, 2024
AxatilimabIdiopathic Pulmonary FibrosisPhase IIActive Not RecruitingMAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Nov 09, 2023
Chemotherapy, RevumenibSolid Tumors, Colorectal Cancerphase1AndPhase2CompletedEvaluation of Revumenib in Participants With Colorectal Cancer and Other Solid TumorsFeb 07, 2023
RevumenibAcute LeukemiaPhase ICompletedStudy of Radiolabeled Revumenib in Adults With Acute LeukemiaJun 01, 2022―
AxatilimabChronic Graft-Versus-Host-DiseasePhase IIActive Not RecruitingA Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)Jan 05, 2021―
Revumenib, CobicistatAcute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia Of Ambiguous Lineage, Mixed Phenotype Acute Leukemiaphase1AndPhase2RecruitingA Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationAug 16, 2019
AxatilimabChronic Graft-Versus-Host-Diseasephase1AndPhase2CompletedA Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHDJul 10, 2018―
Atezolizumab, EntinostatBreast Cancerphase1AndPhase2CompletedRandomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead InMar 09, 2016―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Syndax Pharmaceuticals Inc. (SNDX) have in its pipeline
Syndax Pharmaceuticals SNDX is currently developing the following drugs: Revumenib, Sndx-5613, Revumenib, Intensive Chemotherapy Regimen, Sndx-5613, Chemotherapy Regimen, Hidac, Axatilimab, Chemotherapy, Revumenib, Revumenib, Revumenib, Cobicistat, Atezolizumab, Entinostat, Pembrolizumab, Entinostat. These drug candidates are in various stages of clinical development as the company works toward FDA approval.